Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
贝伐珠单抗联合每周一次阿奈妥单抗或每周一次紫杉醇治疗铂类耐药/难治性高级别卵巢癌的随机 II 期研究（NCI 试验）
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-3128
Alqaisi, Husam A; Cohn, David E; Chern, Jing-Yi; Duska, Linda R; Jewell, Andrea; Corr, Bradley R; Winer, Ira Seth; Girda, Eugenia; Crispens, Marta A; Dhani, Neesha C; Madariaga, Ainhoa; Grant, Robert C; Malaguti, Matthew; Lee, Crystal; Bowering, Valerie; Wong, Horace; Poothullil, Andrew; Speers, Vanessa; Wang, Lisa; Bedard, Philippe L; Brady, John C; Nixon, Andrew B; Chen, Li; O'Connor, Claire; Zamboni, William; McKee, Tawyna; Moscow, Jeffrey A; Oza, Amit M; Lheureux, Stephanie
